Video Experimental Relacionado
Updated: May 27, 2026
07:49
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
La resistencia al inhibidor de RAF está mediada por la dimerización de BRAF empalmado anormalmente (V600E)
Poulikos I Poulikakos1, Yogindra Persaud, Manickam Janakiraman
1Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Nature
|November 25, 2011
Resumen
Un nuevo mecanismo de resistencia a los inhibidores de RAF en el melanoma involucra variantes de empalme BRAF (V600E). Estas variantes promueven la dimerización independiente de RAS, lo que lleva a la reactivación de la vía ERK y la resistencia al vemurafenib en los pacientes.
Área de la Ciencia:
- Oncología Oncología.
- Biología Molecular Biología Molecular
- Resistencia a las drogas Resistencia a las drogas.
Sus antecedentes:
- Los inhibidores de RAF como el vemurafenib son efectivos contra los melanomas BRAF (V600E) al inhibir la señalización de ERK.
- La resistencia a los inhibidores de RAF invariablemente se desarrolla, lo que requiere la identificación de los mecanismos subyacentes.
Objetivo del estudio:
- Identificar nuevos mecanismos de resistencia adquirida al vemurafenib en el melanoma BRAF (V600E).
- Para investigar el papel de las variantes de empalme BRAF ((V600E) en la resistencia al inhibidor de RAF.
Principales métodos:
- Análisis de las células de melanoma resistentes al vemurafenib y los tumores de los pacientes.
- Caracterización de las variantes de empalme BRAF ((V600E), incluyendo p61BRAF ((V600E).
- Evaluación de la formación de dímeros RAF y la actividad de la vía de señalización ERK.
Principales resultados:
- Un subconjunto de células resistentes expresa p61BRAF ((V600E), una variante que carece del dominio de unión al RAS.
- p61BRAF ((V600E) exhibe una dimerización mejorada e independiente de RAS en comparación con el BRAF (V600E) de longitud completa.
- La expresión de p61BRAF ((V600E) confiere resistencia al vemurafenib mediante el mantenimiento de la señalización ERK.
Conclusiones:
- La resistencia adquirida al vemurafenib puede surgir de la expresión de las variantes de empalme BRAF (V600E).
- Estas variantes dimerizan independientemente del RAS, evitando los efectos inhibidores del fármaco.
- Dirigirse a estas variantes de empalme puede ofrecer nuevas estrategias terapéuticas para el melanoma resistente.
Más Videos Relacionados
06:44Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells
Published on: March 1, 2024
10:16Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Videos de Conceptos Relacionados
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...